# Dare Bioscience, Inc. (DARE) — restructuring/exchange_offer [pending]
Source: sec.gov · situation sit_312a316083b9c39fbc43 · public 5269299851118806206 · retrieved 2026-08-19T12:05:49.971Z

## Overview
Darée Bioscience develops pharmaceutical products and operates a 503B compounding business (production and supply of compounded drugs by outsourcing facilities registered under Section 503B of the Federal Food, Drug, and Cosmetic Act) and consumer health business.

On August 14, 2026, Darée Bioscience entered into a securities purchase agreement with institutional investors for a registered direct offering. The company sold 4,085,687 shares of common stock at $1.37 per share, 293,894 pre-funded warrants at $1.3699 per warrant, 4,379,581 Series A Warrants (exercisable at $1.37 per share, expiring five years from shareholder approval), and 4,379,581 Series B Warrants (exercisable at $1.37 per share or pre-funded warrants, expiring two years from shareholder approval). Each share or pre-funded warrant purchased includes one Series A Warrant and one Series B Warrant. The aggregate gross proceeds are expected to be approximately $6.0 million before offering expenses. The closing was expected on or about August 17, 2026, subject to customary closing conditions. The company intends to use proceeds for working capital, general corporate purposes, 503B compounding and consumer health business strategies, research and development, and general and administrative costs.

## Terms
- Counterparty: Institutional investors · Deal value: $6.0M · Consideration: mixed · Price/share: $1.37

## Key dates
- Announced 2026-08-17 · Expected close 2026-08-17

## Timeline
- 2026-08-17 · 8-K (0001493152-26-038649): 8-K - Dare Bioscience, Inc. — *Darée Bioscience develops pharmaceutical products and operates a 503B compounding business (production and supply of compounded drugs by outsourcing facilities registered under Section 503B of the Federal Food, Drug, and Cosmetic Act) and consumer health business.* On August 14, 2026, Darée Bioscience entered into a securities purchase agreement with institutional investors for a registered direct offering. The company sold 4,085,687 shares of common stock at $1.37 per share, 293,894 pre-funded warrants at $1.3699 per warrant, 4,379,581 Series A Warrants (exercisable at $1.37 per share, expiring five years from shareholder approval), and 4,379,581 Series B Warrants (exercisable at $1.37 per share or pre-funded warrants, expiring two years from shareholder approval). Each share or pre-funded warrant purchased includes one Series A Warrant and one Series B Warrant. The aggregate gross proceeds are expected to be approximately $6.0 million before offering expenses. The closing was expected on or about August 17, 2026, subject to customary closing conditions. The company intends to use proceeds for working capital, general corporate purposes, 503B compounding and consumer health business strategies, research and development, and general and administrative costs.
  https://www.sec.gov/Archives/edgar/data/1401914/0001493152-26-038649.txt

## Citations
- 0001493152-26-038649 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000149315226038649